2. Search Result
Search Result
Results for "

cyclic guanosine monophosphate

" in MedChemExpress (MCE) Product Catalog:

53

Inhibitors & Agonists

1

Peptides

15

Natural
Products

6

Isotope-Labeled Compounds

3

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-125153
    Bursin

    		Influenza Virus Others
    Bursin is a peptide that can be isolated from the bursa of Fabricius of chicken. Bursin induces the phenotypic differentiation of mammalian and avian B precursor cells. Bursin also increases cyclic guanosine monophosphate in cells of the human B-cell line Daudi, its derivatives are able to protect against infection by amplifying the immune response induced by H9N2 .
    Bursin
  • HY-N8245
    2',3'-cGMP sodium

    guanosine 2',3'-cyclic monophosphate sodium salt

    		 Drug Intermediate Others
    2',3'-cGMP sodium, a cGMP analogue, is an intermediate of RNA catalytic cleavage by binase .
    2',3'-cGMP sodium
  • HY-17391
    Pamabrom

    		Adenosine Receptor Endocrinology
    Pamabrom is a diuretic that acts on the opioid receptor-nitric oxide (NO) -cyclic guanosine monophosphate (cGMP) -K + channel pathway. It exerts peripheral antinociceptive activity by activating this pathway. The mechanism involves activating opioid receptors, promoting the release of nitric oxide, and then influencing cyclic guanosine monophosphate and K? channels to produce an analgesic effect. Pamabrom is orally active and is mainly used in the research and treatment of premenstrual syndrome and primary dysmenorrhea.
    Pamabrom
  • HY-50723
    3-Methylxanthine

    		Endogenous Metabolite Others
    3-Methylxanthine, a xanthine derivative, is a cyclic guanosine monophosphate (GMP) inhibitor, with an IC50 of 920 μM on guinea-pig isolated trachealis muscle.
    3-Methylxanthine
  • HY-N0097R
    Guanosine (Standard)

    		HSV Endogenous Metabolite Infection
    Guanosine (Standard) is the analytical standard of Guanosine. This product is intended for research and analytical applications. Guanosine (DL-Guanosine) is a purine nucleoside comprising guanine attached to a ribose (ribofuranose) ring via a β-N9-glycosidic bond. Guanosine possesses anti-HSV activity. In Vitro: Guanosine can be phosphorylated to become guanosine monophosphate (GMP), cyclic guanosine monophosphate (cGMP), guanosine diphosphate (GDP), and guanosine triphosphate (GTP). These forms play important roles in various biochemical processes such as synthesis of nucleic acids and proteins, photosynthesis, muscle contraction, and intracellular signal transduction (cGMP).
    Guanosine (Standard)
  • HY-125153A
    Bursin triacetate

    		Others Endocrinology
    Bursin triacetate is a peptide that can be isolated from the bursa of Fabricius in chickens. It promotes the phenotypic differentiation of B precursor cells in both mammals and birds. Bursin triacetate increases cyclic guanosine monophosphate levels in the human B-cell line Daudi .
    Bursin triacetate
  • HY-153092
    Avenciguat

    BI-685509

    		 Guanylate Cyclase Cardiovascular Disease Metabolic Disease
    Avenciguat (BI-685509) is a potent and orally active sGC activator. Avenciguat restores cyclic guanosine monophosphate (cGMP) and improves functionality of nitric oxide (NO) pathways. Avenciguat can be used in research of chronic kidney disease (CKD) and diabetic kidney disease (DKD) .
    Avenciguat
  • HY-153538
    AP-C2

    		Ser/Thr Protease Metabolic Disease
    AP-C2 is a potent guanosine 3',5'-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) inhibitor with a pIC50 of 5.2 .
    AP-C2
  • HY-14841
    Gisadenafil

    UK-369003

    		 Phosphodiesterase (PDE) Neurological Disease
    Gisadenafil (UK-369003) is a specific, orally active phosphodiesterase 5 (PDE5) inhibitor with an IC50 of 3.6 nM and prevents degradation of cyclic guanosine monophosphate (cGMP) .
    Gisadenafil
  • HY-114643
    (Rac)-Tovinontrine

    (Rac)-IMR-687

    		 Phosphodiesterase (PDE) Cardiovascular Disease
    (Rac)-Tovinontrine ((Rac)-IMR-687) is a phosphodiesterase 9 (PDE9) inhibitor that increases cyclic guanosine monophosphate (cGMP) levels. (Rac)-Tovinontrine is promising for research of thalassemia .
    (Rac)-Tovinontrine
  • HY-108619
    Gisadenafil besylate

    UK 369003-26

    		 Phosphodiesterase (PDE) Neurological Disease
    Gisadenafil besylate (UK 369003-26) is a specific, orally active phosphodiesterase 5 (PDE5) inhibitor with an IC50 of 3.6 nM and prevents degradation of cyclic guanosine monophosphate (cGMP) .
    Gisadenafil besylate
  • HY-129210
    KMUP-4

    		Phosphodiesterase (PDE) Potassium Channel Cardiovascular Disease
    KMUP-4, as a xanthine derivative with cGMP-enhancing activity, induces aortic relaxation through endothelium-dependent and independent mechanisms. KMUP-4 increases cytoplasmic cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP) levels by inhibiting phosphodiesterases (PDEs) and activating K + channels. KMUP-4 can be used in the study of cardiovascular diseases .
    KMUP-4
  • HY-153540
    AP-C4

    		PKG Others
    AP-C4 is an inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 5.2. AP-C3 does not inhibit cGKII-dependent anion secretion .
    AP-C4
  • HY-137665
    PET-cGMP

    		PKG Cardiovascular Disease
    PET-cGMP is a cyclic guanosine monophosphate analog and an effective selective agonist of PKG I, the EC50 of PET-cGMP for PKG Iβ is 3.8 nM, while for PKG II, it's 193 nM .
    PET-cGMP
  • HY-153541
    AP-C7

    		PKG Others
    AP-C7 is an inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 5.0. AP-C7 only weakly inhibits cGKII-dependent anion secretion .
    AP-C7
  • HY-P2867
    Phosphodiesterase II, Bovine Spleen

    3′-Exonuclease

    		 Phosphodiesterase (PDE) Neurological Disease
    Phosphodiesterase II (EC 3.1.16.1), namely phosphodiesterase 2, is mainly involved in the hydrolysis of the important second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), and is often used in biochemical research. Phosphodiesterase II is expressed in a variety of tissues, such as the adrenal medulla, brain, heart, platelets, macrophages and endothelial cells, and is involved in the regulation of many different intracellular processes .
    Phosphodiesterase II, Bovine Spleen
  • HY-153539
    AP-C3

    		PKG Others
    AP-C3 is a potent inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 6.3. AP-C3 only weakly inhibits cGKII-dependent anion secretion .
    AP-C3
  • HY-153537
    AP-C1

    		PKG Others
    AP-C1 is a potent inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 6.5. AP-C1 only weakly inhibits cGKII-dependent anion secretion .
    AP-C1
  • HY-145607
    Zagociguat

    CY-6463; IW-6463

    		 Guanylate Cyclase Cardiovascular Disease
    Zagociguat is the stimulator of soluble guanylate cyclase. Zagociguat increases nitric oxide (NO) signaling leading to an increase in cyclic guanosine monophosphate production. Zagociguat has the potential for the research of noncentral nervous system (CNS) disorders .
    Zagociguat
  • HY-117186
    Bis-propargyl-PEG6

    		PROTAC Linkers Metabolic Disease
    Bis-propargyl-PEG6 is a PEG-based PROTAC linker used in the synthesis of PROTACs. Bis-propargyl-PEG6 can be used to synthesize the polymer linked multimers of guanosine-3', 5'-cyclic monophosphates . Bis-propargyl-PEG6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Bis-propargyl-PEG6
  • HY-133190
    Bis-propargyl-PEG7

    		PROTAC Linkers Metabolic Disease
    Bis-propargyl-PEG7 is a PEG-based PROTAC linker used in the synthesis of PROTACs. Bis-propargyl-PEG7 can be used to synthesize the polymer linked multimers of guanosine-3', 5'-cyclic monophosphates . Bis-propargyl-PEG7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Bis-propargyl-PEG7
  • HY-159857
    Gp(2′-5′)Ap sodium

    Gp(2′-5′)Ap(3′) sodium; 2'5'-GpAp sodium; Guanylyl-(2′→5′)-3′-adenylic acid sodium

    		 Others
    Gp(2′-5′)Ap sodium is a linear dinucleotide analog after hydrolysis of cyclic guanosine monophosphate- adenosine monophosphate (2’3’-cGAMP) by phosphodiesterases. Due to its linear conformation, 2’5’GpAp is intended to serve as a negative control for 2’3’-cGAMP in type I IFN induction assays.
    Gp(2′-5′)Ap sodium
  • HY-153542
    AP-C6

    		PKG Others
    AP-C6 is a potent inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 6.5. AP-C6 concentration-dependently inhibits human cGKII activity in vitro. AP-C6 potentiate cAMP signaling by PDE inhibition .
    AP-C6
  • HY-50723R
    3-Methylxanthine (Standard)

    		Endogenous Metabolite Others
    3-Methylxanthine (Standard) is the analytical standard of 3-Methylxanthine. This product is intended for research and analytical applications. 3-Methylxanthine, a xanthine derivative, is a cyclic guanosine monophosphate (GMP) inhibitor, with an IC50 of 920 μM on guinea-pig isolated trachealis muscle.
    3-Methylxanthine (Standard)
  • HY-50723S1
    3-Methylxanthine-d3

    		Endogenous Metabolite Isotope-Labeled Compounds Others
    3-Methylxanthine-d3 is deuterated labeled 3-Methylxanthine (HY-50723). 3-Methylxanthine, a xanthine derivative, is a cyclic guanosine monophosphate (GMP) inhibitor, with an IC50 of 920 μM on guinea-pig isolated trachealis muscle.
    3-Methylxanthine-d3
  • HY-105084
    Lubeluzole

    		Sodium Channel Neurological Disease
    Lubeluzole is a neuroprotective anti-ischemic compound. Lubeluzole, but not its (-)-R-isomer, protects against sensorimotor deficits provoked by photochemical stroke in rats. Lubeluzole inhibited glutamate-stimulated guanosine 3',5'-cyclic monophosphate production with an IC50 of 37 nM. Lubeluzole also has the potential for developing a novel class of antibacterial adjuvants endowed with spasmolytic activity .
    Lubeluzole
  • HY-131454
    SR-717
    Maximum Cited Publications
    13 Publications Verification

    		 STING Inflammation/Immunology Cancer
    SR-717 is a non-nucleotide STING agonist with EC50s of 2.1 μM and 2.2 μM in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cell lines, respectively. SR-717 is a stable cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic. Antitumor activity .
    SR-717
  • HY-131454A
    SR-717 free acid
    Maximum Cited Publications
    13 Publications Verification

    		 STING Inflammation/Immunology Cancer
    SR-717 free acid is a non-nucleotide STING agonist with EC50s of 2.1 μM and 2.2 μM in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cell lines, respectively. SR-717 free acid is a stable cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic. Antitumor activity .
    SR-717 free acid
  • HY-147946
    PDE1-IN-4

    		Phosphodiesterase (PDE) Calcium Channel Inflammation/Immunology
    PDE1-IN-4 (compound 2g) is a potent and selective PDE1 (phosphodiesterase-1) inhibitor, with IC50 values of 10, 145, and 354 nM for PDE1C, PDE1A, and PDE1B, respectively. PDE1-IN-4 inhibits myofibroblast differentiation of human lung fibroblasts induced by TGF-β1. PDE1-IN-4 shows anti-fibrosis effects through the regulation of cAMP (3′,5′-cyclic adenosine monophosphate) and cGMP (3′,5′-cyclic guanosine monophosphate). PDE1-IN-4 can be used for idiopathic pulmonary fibrosis (IPF) research .
    PDE1-IN-4
  • HY-50723S
    3-Methylxanthine-13C4,15N3

    		Endogenous Metabolite Others
    3-Methylxanthine- 13C4, 15N3 is the 13C-labeled and 15N-labeled 3-Methylxanthine. 3-Methylxanthine, a xanthine derivative, is a cyclic guanosine monophosphate (GMP) inhibitor, with an IC50 of 920 μM on guinea-pig isolated trachealis muscle.
    3-Methylxanthine-13C4,15N3
  • HY-130530
    AP-C5

    		Biochemical Assay Reagents Metabolic Disease
    AP-C5 displays selective inhibition of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 7.2, which can be used for the research of diarrheal disease . AP-C5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    AP-C5
  • HY-134311
    8-NBD-cGMP

    		Fluorescent Dye Others
    8-NBD-cGMP is a fluorescent analog of cyclic guanosine monophosphate and a potent, membrane-permeable, fluorescent activator of cGMP-dependent protein kinase isozymes I α and I β. 8-NBD-cGMP is barely fluorescent in aqueous solution but fluoresces strongly in hydrophobic environments such as hydrophobic protein binding sites
    8-NBD-cGMP
  • HY-134263
    8-Br-cAMP-AM

    		PKA Ras Cardiovascular Disease
    8-Br-cAMP-AM is a cyclic adenosine monophosphate (cAMP) analog that activates two major signal transduction pathways in the heart by mimicking the effects of cAMP: protein kinase A (PKA) and guanosine nucleotide exchange factor (Epac), which is directly activated by cAMP. 8-Br-cAMP-AM can be used to study cardiac ischemia and reperfusion injury .
    8-Br-cAMP-AM
  • HY-W654000
    Cyclic GMP-13C,15N2

    guanosine 3',5'-cyclic-13C,15N2 monophosphate

    		 Isotope-Labeled Compounds STING Endogenous Metabolite Inflammation/Immunology
    Cyclic GMP- 13C, 15N2 is 13C and 15N labeled Cyclic GMP. Cyclic GMP (cGAMP) is an endogenous second messenger that triggers interferon production in response to cytoplasmic DNA. Cyclic GMP activates the stimulator of interferon genes (STING), activating a signaling cascade that leads to the production of type I interferons and other immune mediators .
    Cyclic GMP-13C,15N2
  • HY-137108
    Sp-8-pCPT-cGMPS

    		PKA PKG Neurological Disease
    Sp-8-pCPT-cGMPS is a potent cyclic guanosine monophosphate-gated channel agonist and a lipophilic activator of protein kinase G (types I α, I β, and II) and protein kinase A type II with excellent cell membrane permeability and phosphodiesterase stability. Sp-8-pCPT-cGMPS can be used to study the role of cGMP in neural plasticity and synaptic transmission .
    Sp-8-pCPT-cGMPS
  • HY-B0442C
    Vardenafil dihydrochloride

    		Endogenous Metabolite Phosphodiesterase (PDE) Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .
    Vardenafil dihydrochloride
  • HY-B0442
    Vardenafil
    2 Publications Verification

    		 Phosphodiesterase (PDE) Endogenous Metabolite Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes [1]-[6].
    Vardenafil
  • HY-B0442A
    Vardenafil hydrochloride
    2 Publications Verification

    		 Phosphodiesterase (PDE) Endogenous Metabolite Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes [1]-[6].
    Vardenafil hydrochloride
  • HY-B0442S
    Vardenafil-d5

    		Phosphodiesterase (PDE) Endogenous Metabolite Endocrinology
    Vardenafil-d5 is deuterium labeled Vardenafil. Vardenafil is a selective, orally active, potent inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil shows selectivity over PDE1 (180 nM), PDE6 (11 nM), PDE2, PDE3, and PDE4 (>1000 nM). Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil can be used for the research of erectile dysfunction[1][2].
    Vardenafil-d5
  • HY-117803
    CP 461 free base

    OSI-461 free base

    		 Apoptosis Cancer
    CP 461 free base (OSI-461 free base) is a novel pro-apoptotic compound with the activity of inhibiting cyclic guanosine monophosphate phosphodiesterase. CP 461 free base exhibits growth inhibitory activity against a variety of human tumor cell lines in vitro. CP 461 free base selectively induces apoptosis in cancer cell lines but has no effect on normal cells. CP 461 free base can be used in the study of renal cell carcinoma, prostate cancer and Crohn's disease .
    CP 461 free base
  • HY-B0442B
    Vardenafil hydrochloride trihydrate
    2 Publications Verification

    		 Endogenous Metabolite Phosphodiesterase (PDE) Metabolic Disease Inflammation/Immunology Endocrinology
    Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes [1]-[6].
    Vardenafil hydrochloride trihydrate
  • HY-105349
    T-0156

    		Phosphodiesterase (PDE) Neurological Disease
    T-0156 is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. T-0156 specifically inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) by PDE5 in a competitive manner (IC50=0.23 nM). T-0156 inhibits PDE6 (IC50=56 nM) and has low potencies against PDE1, PDE2, PDE3, and PDE4 (IC50>10 μM). T-0156 enhances the nitric oxide (NO)/cGMP pathway .
    T-0156
  • HY-B0442CR
    Vardenafil (dihydrochloride) (Standard)

    		Endogenous Metabolite Phosphodiesterase (PDE) Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .
    Vardenafil (dihydrochloride) (Standard)
  • HY-B0442R
    Vardenafil (Standard)

    		Phosphodiesterase (PDE) Endogenous Metabolite Metabolic Disease Inflammation/Immunology Endocrinology
    Vardenafil (Standard) is the analytical standard of Vardenafil. This product is intended for research and analytical applications. Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes [1]-[6].
    Vardenafil (Standard)
  • HY-W049735R
    N,N,O-Tridesmethylvenlafaxine (Standard)

    		Drug Metabolite Endogenous Metabolite Metabolic Disease
    Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .
    N,N,O-Tridesmethylvenlafaxine (Standard)
  • HY-B0442AS
    Vardenafil-d5 hydrochloride

    		Endogenous Metabolite Phosphodiesterase (PDE) Isotope-Labeled Compounds Metabolic Disease Inflammation/Immunology Endocrinology
    Vardenafil-d5 hydrochloride is deuterated labeled Vardenafil hydrochloride (HY-B0442A). Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes [1]-[6].
    Vardenafil-d5 hydrochloride
  • HY-B0442BR
    Vardenafil hydrochloride trihydrate (Standard)

    		Endogenous Metabolite Phosphodiesterase (PDE) Metabolic Disease Inflammation/Immunology Endocrinology
    Vardenafil (hydrochloride trihydrate) (Standard) is the analytical standard of Vardenafil (hydrochloride trihydrate). This product is intended for research and analytical applications. Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes - .
    Vardenafil hydrochloride trihydrate (Standard)
  • HY-164685
    T-0156 free base

    		Phosphodiesterase (PDE) Neurological Disease
    T-0156 free base is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. T-0156 free base specifically inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) by PDE5 in a competitive manner (IC50=0.23 nM). T-0156 free base inhibits PDE6 (IC50=56 nM) and has low potencies against PDE1, PDE2, PDE3, and PDE4 (IC50>10 μM). T-0156 free base enhances the nitric oxide (NO)/cGMP pathway .
    T-0156 free base
  • HY-18252
    Avanafil
    1 Publications Verification

    TA1790

    		 Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite Cardiovascular Disease Endocrinology
    Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .
    Avanafil
  • HY-18252R
    Avanafil (Standard)

    		Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite Cardiovascular Disease Endocrinology
    Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .
    Avanafil (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: